Our Science – Wunderlich Website
John R. Wunderlich, M.D.
Selected Publications |
 |
| 1)
Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J. Clin. Oncol. [Epub ahead of print], 2013. [Journal] |
|
| 2)
Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US. Minimally invasive liver resection to obtain tumorinfiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol. 10: 113, 2012. [Journal] |
|
| 3)
Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res. 18: 5212-23, 2012. [Journal] |
|
| 4)
Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. J. Immunother. 35: 400-8, 2012. [Journal] |
|
| 5)
Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 117: 361-71, 2011. [Journal] |
|
| 6)
Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J. Immunother. 34: 397-402, 2011. [Journal] |
|
| 7)
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clin Cancer Res. 17: 4550-7, 2011. [Journal] |
|
| 8)
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-24, 2011. [Journal] |
|
| 9)
Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich J, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot C, Rosenberg SA. CD8+ enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melenoma. Clin Cancer Res. 16: 6122-31, 2010. [Journal] |
|
| 10)
Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 33: 547-56, 2010. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/16/2013.
